TY - JOUR T1 - Both low-dose and micro-dose 17β-oestradiol reduced hot flushes JF - Evidence Based Medicine JO - Evid Based Med SP - 43 LP - 43 DO - 10.1136/ebm.13.2.43 VL - 13 IS - 2 A2 - , Y1 - 2008/04/01 UR - http://ebm.bmj.com/content/13/2/43.abstract N2 - G A BachmannDr G A Bachmann, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, USA; gloria.bachmann@umdnj.eduDesign:randomised, placebo-controlled trial.Allocation:concealed.*Blinding:blinded (patients, healthcare providers, and data collectors).*Setting:48 centres in the USA.Patients:425 healthy postmenopausal women ⩾40 years of age (mean age 53 y, mean time since menopause 9 y) who had an average of ⩾7 (mean 10) moderate or severe hot flushes per day for ⩾1 week during screening. Exclusion criteria included abnormal Pap test result, abnormal vaginal bleeding, and a history of thrombophlebitis or thromboembolic disorder.Intervention:transdermal patches delivering 0.023 mg/day 17β-oestradiol (E2) plus 0.0075 mg/day levonorgestrel (low-dose group, n = 145), 0.014 mg/day E2 (micro-dose group, n = 147), or no E2 (placebo group, n = 133).Outcomes:frequency and severity of hot … ER -